Results 181 to 190 of about 2,846 (197)

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)†

Cancer, 2012
Monika E Hegi, Joy Fisher, L Burt Nabors
exaly  

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

Annals of Oncology, 2014
Ricard Mesia, P M Clement, J B Vermorken
exaly  

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

European Journal of Cancer, 2003
W Wynendaele, H Dumez, A T van Oosterom
exaly  

Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.

Neuro-Oncology, 2013
Amar Gajjar, Clinton F Stewart, Gilbert Vezina   +2 more
exaly  

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

Investigational New Drugs, 2012
Christian Dr. Manegold, Penella Woll, Johan Vansteenkiste   +2 more
exaly  

A comparative assessment of the effects of integrin inhibitor cilengitide on primary culture of head and neck squamous cell carcinoma (HNSCC) and HNSCC cell lines

Clinical and Translational Oncology, 2019
Aydın Gülses, Jörg Weimer, Y Acil
exaly  

Formulation development of a highly concentrated suspension of Cilengitide

2015
openaire   +1 more source

Integrin αvβ3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non–small-cell lung cancer models

International Journal of Radiation Oncology Biology Physics, 2006
Ling Geng, Carolyn Cao, Jeffrey M Albert
exaly  

Faculty Opinions recommendation of Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2010
Alba Brandes, Enrico Franceschi
openaire   +1 more source

[Cilengitide: a new weapon against glioblastoma?].

Tumori, 2009
openaire   +1 more source